“…Here, we evaluated analytical similarity of CT-P6, a biosimilar product of trastuzumab, with the reference products (EU-Herceptin® or US-Herceptin®) following these statistical approaches. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The MultiPath test detected all toxinotypes and ribotypes tested, including the one most commonly occurring in the US and EU; shows no cross reactivity with relevant bacterial species; and is robust to potential interferants commonly present in stool samples. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Gali has a substantial policy use within the EU and its Member States. The objective of current paper is to bring together what is known from published manuscripts on the validity and the reliability of GALI. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Indeed, this model can be updated to process new information on vectors and the changing health situation, in addition to new data from the TRAde Control and Expert System (TRACES, EU database). This model is easy to adapt to different countries and to other vectors and diseases.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Our CIRPI system combined two imaging modalities: Circumferential Radioluminescence Imaging (CRI) and PhotoAcoustic Tomography (PAT) within a novel optical probe. The probe’s CaF(2):Eu based scintillating imaging window provides a 360° view of human (n = 7) and murine carotid (n = 10) arterial plaques by converting β-particles into visible photons during (18)F-FDG decay. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We test the framework with a multi-scale assessment of habitat suitability for two plant species of conservation concern, both protected under the EU Habitats Directive, differing in terms of life history, range and distribution pattern (Iris boissieri and Taxus baccata). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Six major objectives for health workforce policy were identified: (1) to develop frameworks that align health systems/governance and health workforce policy/planning, (2) to explore the effects of changing skill mixes and competencies across sectors and occupational groups, (3) to map how education and health workforce governance can be better integrated, (4) to analyse the impact of health workforce mobility on health systems, (5) to optimise the use of international/EU, national and regional health workforce data and monitoring and (6) to build capacity for policy implementation. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Health literacy levels were assessed using the HLS-EU 47 item instrument in phase 1 (68% limited health literacy (HL), 32% adequate health literacy). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The statin use increased from 42.347 DDD/TID in 2013 to 71.697 DDD/TID in 2016, although it is lower in comparison to other European Union (EU) countries (1.1–2.5-fold). CONCLUSION: The rapid increase in the consumption of statins can be attributed mostly to an increase in the consumption volume. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND AND AIMS: Estimating ‘return on investment’ (ROI) from smoking cessation interventions requires reach and effectiveness parameters for interventions for use in economic models such as the EQUIPT ROI tool (http://roi.equipt.eu). This paper describes the derivation of these parameter estimates for England that can be adapted to create ROI models for use by other countries. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…A total of 6,306, 9,961, 13,170, 15,484, and 23,588 unigenes were annotated in the clusters of orthologous groups, gene ontology categories, Kyoto Encyclopedia of Genes and Genomes Pathway, euKaryotic orthologous groups, and NCBI non-redundant protein databases, respectively. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…RESULTS: UK overseas graduates were more likely to be deemed appointable compared with non-EU medical graduates who were not UK citizens (OR 1.29, 95% CI 1.16 to 1.42), although less so than UK (OR 0.25, 95% CI 0.23 to 0.27) or European graduates (OR 0.66, 95% CI 0.58 to 0.75). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We use data collected from patients from five countries who used the ICT4Depression/MoodBuster platform in the context of the EU E-COMPARED project. In total, we used the data from 143 patients (with between 9 and 425 days of EMA data) who were diagnosed with a major depressive disorder according to DSM-IV. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We applied the evaluation framework developed by the EU COST Action “Network of Evaluation of One Health” (NEOH) to assess the operations, supporting infrastructures and outcomes of a research consortium “University of Copenhagen Research Centre for Control of Antibiotic Resistance” (UC-CARE). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Cysteamine bitartrate delayed-release (DR) capsule (Procysbi(®)) is approved for treatment of nephropathic cystinosis in the USA, Canada, and the EU. The capsules contain cysteamine bitartrate beads that are enteric coated with acid-resistant Eudragit L 30 D-55, preventing drug release in the acidic stomach environment while allowing dissolution of the beads in the more alkaline environment of the small intestine. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…When confirmed in a larger, placebo-controlled trial, this minimal invasive procedure has the potential to become first-line therapy for FI. TRIAL REGISTRATION: EU Clinical Trials Register, EudraCT 2010-023826-19 (Date of registration: 08.11.2010).…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Registered 05 May 2017, https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003986-25…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…DISCUSSION: This is the first study evaluating in-vivo transplacental passage of sildenafil in humans. TRIAL REGISTRATION: EU Clinical Trials Register 2016–002619-17, validated on 12 August 2016. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…This clinical trial was registered at the EU Clinical Trials Register before patient recruitment (Registration number: EudraCT number 2012-005599-33; Date of registration: 2013-02-04).…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: This study was a randomized, single-blind, single-dose, parallel-group study comparing PK parameters of ABP 215 versus EU-authorized bevacizumab in healthy Japanese men. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso